alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
1The Honorable William R. Wilson, Jr., United States District Judge for the

Eastern District of Arkansas.

United States Court of Appeals

FOR THE EIGHTH CIRCUIT

___________

No. 98-3018

___________

United States of America, *

 *

Appellee, *

 * Appeal from the United States

v. * District Court for the

 * Eastern District of Arkansas. 

Ronald M. Thomas, *

 * [UNPUBLISHED]

Appellant. *

___________

 Submitted: March 7, 2000

 Filed: March 27, 2000

___________

Before McMILLIAN, RICHARD S. ARNOLD, and BEAM, Circuit Judges. 

___________

PER CURIAM.

Ronald Thomas challenges the district court’s1 judgment, entered on a jury

verdict, finding him guilty of possession with intent to distribute cocaine base, in

violation of 21 U.S.C. § 841(a)(1). For reversal, he argues the government presented

insufficient evidence to convict him. However, viewing the evidence in the light most

favorable to the jury’s verdict and giving the verdict the benefit of all reasonable
-2-

inferences, see United States v. Buford, 108 F.3d 151, 153 (8th Cir. 1997), we

conclude ample evidence of Thomas’s guilt was adduced at trial, see United States v.

Perkins, 94 F.3d 429, 436 (8th Cir. 1996) (elements of § 841(a)(1) offense), cert.

denied, 519 U.S. 1136 (1997). 

Accordingly, we affirm.

A true copy.

Attest:

CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
[Federal Register Volume 88, Number 235 (Friday, December 8, 2023)]
[Notices]
[Page 85646]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26943]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Deafness and Other Communication Disorders; 
Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Deafness and Other 
Communication Disorders Special Emphasis Panel; Research 
Opportunities for New Investigators to Promote Workforce Diversity.
    Date: December 12, 2023.
    Time: 12:00 p.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Andrea B. Kelly, Ph.D., Scientific Review 
Officer, National Institute on Deafness and Other Communication 
Disorders, National Institutes of Health, 6001 Executive Boulevard, 
Room 8351, Bethesda, MD 20892, (301) 451-6339, <a href="/cdn-cgi/l/email-protection#2e454b4242574f1c6e40474600494158"><span class="__cf_email__" data-cfemail="bcd7d9d0d0c5dd8efcd2d5d492dbd3ca">[email protected]</span></a>.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.173, 
Biological Research Related to Deafness and Communicative Disorders, 
National Institutes of Health, HHS)

    Dated: December 4, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-26943 Filed 12-7-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
[Federal Register Volume 88, Number 234 (Thursday, December 7, 2023)]
[Notices]
[Page 85333]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26827]


-----------------------------------------------------------------------

POSTAL SERVICE


Product Change--Priority Mail and USPS Ground Advantage[supreg] 
Negotiated Service Agreement

AGENCY: Postal Service<SUP>TM</SUP>.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Postal Service gives notice of filing a request with the 
Postal Regulatory Commission to add a domestic shipping services 
contract to the list of Negotiated Service Agreements in the Mail 
Classification Schedule's Competitive Products List.

DATES: Date of required notice: December 7, 2023.

FOR FURTHER INFORMATION CONTACT: Sean Robinson, 202-268-8405.

SUPPLEMENTARY INFORMATION: The United States Postal Service[supreg] 
hereby gives notice that, pursuant to 39 U.S.C. 3642 and 3632(b)(3), on 
November 20, 2023, it filed with the Postal Regulatory Commission a 
USPS Request to Add Priority Mail & USPS Ground Advantage[supreg] 
Contract 109 to Competitive Product List. Documents are available at 
www.prc.gov, Docket Nos. MC2024-66, CP2024-67.

Sean Robinson,
Attorney, Corporate and Postal Business Law.
[FR Doc. 2023-26827 Filed 12-6-23; 8:45 am]
BILLING CODE 7710-12-P
EX-32.1








SECTION
      906 CERTIFICATION





CERTIFICATION





Pursuant
      to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley
      Act of 2002:





In
      connection with the Quarterly Report of Franklin lake Resources Inc. ("Company")
      on Form 10-QSB for the Fiscal Quarter Ended January 31, 2007, as filed with
      the
      Securities and Exchange Commission on the date hereof ("Report"), I, Father
      Gregory Ofiesh, as Chief Executive Officer and Acting Chief Financial Officer
      of
      the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant
      to
      Sec. 906 of the Sarbanes-Oxley Act of 2002, that:





(1)  the
      Report fully complies with the requirements of Sec. 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and





(2)  the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.







Dated:  March
      14,
      2007                                                                            /s/Father
      Gregory Ofiesh


Father Gregory Ofiesh


President & CEO and Acting


Chief Financial Officer
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                      23,886,464
<SECURITIES>                                         0
<RECEIVABLES>                                1,702,085
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            25,588,549
<PP&E>                                     114,526,538
<DEPRECIATION>                              48,732,516
<TOTAL-ASSETS>                              91,382,738
<CURRENT-LIABILITIES>                          935,316
<BONDS>                                     45,801,266
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  44,646,156
<TOTAL-LIABILITY-AND-EQUITY>                91,382,738
<SALES>                                              0
<TOTAL-REVENUES>                            12,307,505
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                            10,703,772
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             886,502
<INCOME-PRETAX>                                717,231
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            717,231
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   717,231
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
[Federal Register Volume 88, Number 233 (Wednesday, December 6, 2023)]
[Notices]
[Page 84823]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26790]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Small Business for Endocrine, Metabolic Systems and 
Reproduction.
    Date: December 15, 2023.
    Time: 3:30 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Dianne Hardy, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 6175, MSC 7892, Bethesda, MD 20892, 301-435-
1154, <a href="/cdn-cgi/l/email-protection#117578707f7f743f7970637568517f78793f767e67"><span class="__cf_email__" data-cfemail="4d29242c23232863252c3f29340d232425632a223b">[email protected]</span></a>.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and funding 
cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: December 1, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-26790 Filed 12-5-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit 23.1

CONSENT OF MOSS ADAMS, LLP, 
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the previously filed Registration Statements (Form S-8, Nos. 333-109502 and 333-109473) of our report dated April 16, 2007, relating to the consolidated financial statements of Global Aircraft Solutions, Inc. (formerly Renegade Venture Corporation) and our report dated April 17, 2007 related to the Jetglobal LLC financial statements, included in this Annual Report (Form 10-K) for the year ended December 31, 2007.
/s/ MOSS ADAMS LLPScottsdale, Arizona
April 10, 2008

---
Exhibit 23



CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM



We hereby consent to the incorporation by reference in the registration statements of Indevus Pharmaceuticals, Inc. on Form S-8 (File Nos.
33-58742, 33-76652, 33-94730, 333-24969, 33-94736, 333-40315, 333-48911, 333-40572, 333-104094, 333-104095 and 333-115921) and on Form S-3 (File Nos. 33-75826, 333-01273, 333-03131, 333-18001, 333-76338 and 333-109263) of our report dated December
13, 2004, relating to the consolidated financial statements of Indevus Pharmaceuticals, Inc., which appears in this Annual Report on Form 10-K. We also consent to the reference to us under the heading Selected Financial Data in such Form
10-K.



|                                  |  | 
|--------------------------------- |  | 
|                                 
|/s/    PricewaterhouseCoopers LLP
|                                 
|Boston, Massachusetts            
|December 14, 2004
Breadcrumb

1. Home

2. Print 

3. Pdf 

4. Node 

5. Entity Print 

About Biotechnology Regulatory

Services

Last Modified: 

Print

APHIS' Biotechnology Regulatory Services uses a science-and risk-based system to

ensure organisms developed using genetic engineering don't pose a plant pest risk.

These organisms include genetically modified plants, insects, and microbes. We set

regulatory requirements for these products and oversee their safe importation,

interstate movement, and environmental release.

BRS coordinates work across two main areas: Risk Analysis Programs conducted

at APHIS Headquarters in Riverdale, MD, and Regulatory Operations Programs

with offices in Fort Collins, CO, and Raleigh, NC. We also have several units that

support all of BRS' work, including our science advisors and Communications;

Intergovernmental Operations; Policy, Program, and International Collaboration; and

Resource Management Services branches.

BRS At-a-Glance

Here's a snapshot of our accomplishments in 2022 (15.96 MB).

USDA's revised biotechnology regulations provide over $8 million in annual cost

savings
Issued 2 Regulatory Status Review (RSR) decisions, the first under the new RSR

process in the revised regulations

Responded to 9 requests for confirmation that a plant met the criteria for

exemption from regulation, confirming all 9 and issuing responses within an

average of 39 days from receiving the requests

With State agricultural officials, performed more than 660 inspections of

authorized field trials involving organisms developed using genetic engineering,

with an 88-percent rate of compliance

Completed 1 petition for nonregulated status under the legacy regulations,

bringing the total number of determinations to 136

Delivered more than 13 presentations to international stakeholders

representing 40 countries to offer technical information and build capacity

abroad for regulating biotechnology

Processed over 758 authorizations in 42 States for the movement or field

testing of organisms developed using genetic engineering

Stay in the Know

For the latest news about biotechnology, sign up for email updates.

Subscribe

Need help from Biotechnology Regulatory Services?

Visit Our Biotechnology Contacts Directory
`Exhibit 10.6


                   AMENDMENT TO APPLEBEE'S INTERNATIONAL, INC.
                 AMENDED AND RESTATED 1995 EQUITY INCENTIVE PLAN


     This  Amendment is adopted this 9th day of December,  2004,  by  Applebee's
International, Inc., a Delaware corporation (the "Company").

     WHEREAS, the Company has adopted the Applebee's International, Inc. Amended
and Restated 1995 Equity Incentive Plan (the "Plan");

     WHEREAS,  the Company  desires to amend the Plan to provide for  additional
flexibility  for officers upon  retirement and upon  termination of service as a
director, and to clarify the ability to transfer awards under the Plan; and

     WHEREAS,  in accordance  with Section 12.1 of the Plan, this Amendment does
not require the approval of the stockholders of the Company.

     NOW, THEREFORE, effective as of the date hereof, the Plan is hereby amended
as follows:

     1.   Section 5.4.1(e) is amended to read in its entirety as follows:

     "(e) The  expiration  of three  (3) years  from the date of the  Optionee's
     Retirement  (except as provided in Section 5.8.2 regarding  Incentive Stock
     Options), or as otherwise set forth in the Award Agreement."

     2.   Section 9.7(b) is amended to read in its entirety as follows:

     "The expiration of one (1) year from the date of the Nonemployee Director's
     termination  of service as a Director for any reason,  or as otherwise  set
     forth in the Award Agreement."

     3.   Section 11.7 is amended to read in its entirety as follows:

     "Section 11.7.  Transferability.  Except as otherwise set forth in an Award
     Agreement,  no Award  granted  under  this  Plan may be sold,  transferred,
     pledged,  assigned,  or otherwise alienated or hypothecated,  other than by
     will,  by the laws of descent and  distribution,  or to the limited  extent
     provided in Section 11.6."

     Except as provided above,  the Plan is hereby ratified and confirmed in all
respects.`

---

`IN WITNESS  WHEREOF,  the Company has hereby  executed this Amendment as of
this 9th day of December, 2004.

                                      APPLEBEE'S INTERNATIONAL, INC.



                                      By:    /s/ Rebecca R. Tilden
                                         ---------------------------------------
                                      Name:      Rebecca R. Tilden
                                      Title:     Vice President, General Counsel
                                                 and Secretary`
Exhibit 32.1**Certification pursuant to****Securities Exchange Act Rule 13a-14(b) or Rule 15d-14(b)**I, Eric R. Zimmerman, President, and Chief Executive Officer of Dayton Superior Corporation (the“Company”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906of the Sarbanes-Oxley Act of 2002, that, to my knowledge:The Annual Report on Form 10-K of the Company for the period ending December 31, 2007 (the“Periodic Report”) fully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) andThe information contained in the Periodic Report fairly presents, in all material respects,the financial condition and results of operations of the Company.Dated: March 17, 2008           /s/ Eric R. Zimmerman   Eric R. Zimmerman    President and Chief Executive Officer
22666

#### State v. Carlsen

Affirmed
Order entered November 10, 2015

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-15-01324-CV

IN RE HICKORY TRAIL HOSPITAL, LP D/B/A HICKORY TRAIL HOSPITAL,

Relator

Original Proceeding from the 160th Judicial District Court

Dallas County, Texas

Trial Court Cause No. DC-14-00726

ORDER

Before Justice Francis, Justice Myers and Justice Schenck

Based on the Court’s opinion of this date, we DENY the petition for writ of mandamus. 

We ORDER relator to bear the costs of this original proceeding.

/s/ MOLLY FRANCIS 

JUSTICE
NPRM Economic Evaluation

Docket No. FAA - 2013 - 0938 Directorate ID 2012 - SW - 057 - AD **Costs of Compliance** We estimate that this proposed AD would affect 37 helicopters of U.S. Registry . We estimate that operators may incur the following costs in order to compl y with this AD. At an average labor rate of $85 per hour, inspecting LH and RH frame No. 9 would require about 3 work- hours, for a cost per helicopter of $255 and a total cost to U.S. operators of $9,435 per inspection cycle. Repairing a cracked frame No. 9 would require about 20 work - hours, and required parts would cost about $10,000, for a cost per helicopter of $11,700.
EXHIBIT
32.1




CERTIFICATION
OF PRINCIPAL EXECUTIVE


PURSUANT
TO 18 U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO SECTION 906


OF THE
SARBANES-OXLEY ACT OF 2002




In
connection with the filing by Applied Energetics, Inc. (the “company”) of its
Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2008
(the “Report”) I, Joseph C. Hayden, Principal Executive Officer of the company,
certify pursuant to 18 U.S.C. Section. 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 that:




(i)
            the
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and




(ii)
            the
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operation of the
      company.




This
certificate is being made for the exclusive purpose of compliance by the
principal executive officer of Applied Energetics, Inc. with the
requirements of Section 906 of the Sarbanes-Oxley Act of 2002, and may not be
used for any other purposes. A signed original of this written statement
required by Section 906 has been provided to Applied Energetics, Inc. and will
be retained by Applied Energetics, Inc. and furnished to the Securities and
Exchange Commission or its staff upon request.




/s/ Joseph C. HaydenJoseph
      C. HaydenChief
      Operating Officer and Principal Executive
  Officer





Date: May
11, 2009
#### Stout v. Tradewind Ins. Co., Ltd.

16697

5/22/97

Denied

85 Hawai'i 177, 938 P.2d 1196
#### Charles B. MARTIN, Appellant, v. Charles S. COFFEY, Receiver of First National Bank of Chattanooga, Appellee. Mrs. Nannie MARTIN, Appellant, v. Charles S. COFFEY, Receiver of First National Bank of Chattanooga, Appellee (J. Buckner Fisher substituted for Chas. S. Coffey, Receiver).

Nos. 8011, 8012.

Circuit Court of Appeals, Sixth Circuit.

Nov. 13, 1939.

Thomas S. Myers, of Chattanooga, Tenn., for Chas. B. Martin and Mrs. Nannie Martin.

S. Bartow Strang, of Chattanooga, Tenn., for Chas. S. Coffey, receiver.

Before HICKS, SIMONS, and ARANT, Circuit Judges.

PER CURIAM.

This cause was heard on the transcript, briefs and argument of counsel.

Upon consideration whereof, it is ordered and adjudged that the judgments appealed from, be and the same are affirmed upon the authority of Silk v. Ake, 6 Cir., 83 F.2d 618, and Crawford v. Gamble, 6 Cir., 57 F.2d 15.
April 13, 2007

27794

#### State v. Holau

Affirmed